<DOC>
	<DOCNO>NCT01728311</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability pharmacokinetics BAY1082439</brief_summary>
	<brief_title>Open Label Study BAY1082439 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Subjects advance , histologically cytologically confirm solid tumor , refractory standard therapy , standard therapy available , subject must actively refuse treatment would regard standard , / judgment investigator , experimental treatment clinically ethically acceptable Expansion phase : Subjects histologically cytologically confirm , locally advanced metastatic endometrial cancer breast cancer iNHL , refractory exhaust available therapy International normalize ratio ( INR ) partial thromboplastin time ( PTT ) &lt; 1.5 x ULN [ Subjects anticoagulation agent coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist . ] For subject warfarin , close monitoring least weekly evaluation perform INR stable base measurement predose , define local standard care Measurable evaluable disease Life expectancy least 12 week Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Adequate bone marrow , liver renal function History cardiac disease : congestive heart failure &gt; New York Heart Association ( NYHA ) Class II , unstable angina ( anginal symptom rest ) , newonset angina ( within past 3 month prior first dose study drug ) , myocardial infarction within past 6 month prior first dose study drug , cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management History diabetes mellitus gestational diabetes mellitus Fasting blood glucose level &gt; 125 mg/dL HbA1c 7 % screen Active clinically serious infection &gt; Grade 2 History organ allograft Seizure disorder require therapy ( steroids antiepileptic )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>